FDA grants nod to Bristol-Myers' Ixempra

10/16/2007 | Wall Street Journal, The

Bristol-Myers Squibb Co. on Tuesday obtained regulatory approval for its chemotherapy drug Ixempra, also known as ixabepilone, for the treatment of advanced breast cancer. The FDA allowed Bristol-Myers to market Ixempra as a stand-alone treatment for use in women who have failed treatment on three other types of chemotherapy and in combination with Xeloda, a chemotherapy treatment from Roche Holding, to fight breast cancer metastasis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI